9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

Cancer Chemotherapy and Pharmacology

Volumn 18, Issue 2, 1986, Pages 145-152

  Danhauser, Lynn ^a   Plunkett, William ^a   Keating, Michael ^a   Cabanillas, Fernando ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; ARABINONUCLEOTIDES; DNA; HUMAN; KINETICS; LEUKEMIA; LYMPHOMA; SUPPORT, U.S. GOV'T, P.H.S.; VIDARABINE PHOSPHATE;

EID: 0022991391     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/BF00262285     Document Type: Article

References (32)

1. 2-Fluoro-ATP: A toxic metabolite of 9-β-D-arabinofuranosyl-2-fluoroadenine
2. Metabolic effects of 9-β-D-arabinofuranosylpurines in ascites tumor cells
3. Biologic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-β-D-arabinofuranosyladenine
4. Metabolism and chemotherapeutic activity of 9-β-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase
5. Enhancement of 9-β-D-arabinofuranosyl-adenine cytotoxicity to mouse leukemic L1210 in vitro by 2′-deoxycoformycin
6. Comparative pharmacokinetics and metabolism of fludarabine phosphate (NSC 312887) in man and dog
7. Some effects of D-arabinosyl nucleosides on polymer synthesis in mouse fibroblasts
8. Differences in metabolism and cytotoxicity between 9β-D-arabinofuranosyladenin and 9-β-D-arabinofuranosyl-2-fluoradenine in human leukemia lymphoblasts
9. A phase I investigation of 2-fluoro-ara-AMP in refractory leukemia
10. Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite
11. High-dose cytosine arabinoside in non-Hodgkin's lymphoma
12. Studies of 9-β-D-arabinofuranosyladenine in man
13. Enhancement of the antitumor activity of arabinofuranosyladenine by 2′-deoxycoformycin
14. The relationship of 1-β-D-arabinofuranosylcytosine in plasma to 1-β-D-arabinofuranosylcytosine 5′-triphosphate levels in leukemic cells during treatment with high dose 1-β-D-arabinofuranosylcytosine
15. Pharmacokinetics of 2-F-ara-AMP in man during a phase I clinical trial
16. Phase II trial of 2-fluoro-ara-AMP (fludarabine phosphate) in patients with advanced breast cancer
17. Nucleosides of 2-fluoroadenin
18. An improved procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoradenine
19. Disposition of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs
20. Toxicity, metabolism, and incorporation into DNA and RNA of arabinosyl-2-fluoroadenine (F-ara-A)
21. Two approaches that increase the activity of analogs of adenine nucleotides in animal cells
22. Comparison of the toxicity and metabolism of 9-β-D-arabinofuranosyl-2-fluoroadenine and 9-β-D-arabinofuranosyladenine in human lymphoblastoid cells
23. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy
24. Modulation of 9-β-D-arabinofuranosyladenine 5′-triphosphate and deoxyadenosine during therapy with 9-β-D-arabinofuranosyladenine
25. Pharmacologically directed ara-C therapy for refractory leukemia
26. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and duration of remission in patients with acute nonlymphocytic leukemia
27. Correlation between leukemic cell retention of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy
28. The antiviral activity of 9-β-D-arabinofuranosyladenine (ara-A)
29. Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect
30. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells
31. Phase I–II clinical trial of fludarabine phosphate in acute leukemia
32. Comparisons of the actions of 9-β-D-arabinofuranosyl-2-fluoroadenine on target enzymes from mouse tumor cells